Loading…
← CockpitCompetitor Analysis › TFX Teleflex IncorporatedOpen in the cockpit ↗

Teleflex IncorporatedTFXCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of single-use medical devices for vascular access, surgical, interventional and urology procedures.

Momentum leader 93
Mkt cap
$6.58B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$136M
20-day average traded
Fwd P/E
16.7×
forward earnings
ROIC−WACC
-3.9 pp
WACC 8.6%
Hurdle
+21 pp
Req g minus delivered
Next earnings
99 days
25 Feb 2027
Close · USD$165.85
1D+4.0%
1W+6.1%
1M+26.5%
3M+22.9%
6M+22.7%
YTD+35.9%
1Y+59.7%
ATR %2.9%
Beta0.51
52w lowhigh0.5% off high

What Teleflex does

Maker of single-use medical devices for vascular access, surgical, interventional and urology procedures.

Sells disposable devices that are used once per procedure, so revenue recurs with procedure volumes rather than depending on one-off equipment sales. Hospitals buy through its own sales force, distributors and supply contracts. Its vascular access and interventional lines carry the business.

Products and services

  • Vascular access devices
  • Interventional (urology, OEM)
  • Surgical devices

Customers

  • Hospitals
  • Anesthesiologists/surgeons
  • Interventional/urology specialists

Where it sits in the supply chain

  • Healthcare
  • Medical devices
  • Vascular access and…

What could go right

  • Vascular access procedure volume growth
  • OEM/interventional urology growth

What could go wrong

  • Hospital purchasing consolidation (GPO) pricing pressure
  • Pending business-unit divestitures/restructuring

Moat: narrow (scale, switching costs, installed base). Broad catalog of clinically embedded single-use devices with established hospital contracts.

Headquarters: Wayne, Pennsylvania, USA · Founded: 1943 · Employees: 15,500

Named competitors

Teleflex at a glance

Size Teleflex (TFX) is a United States Health Care company (Medical Specialties) with a market value of $6.58B, the 992nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $165.85 on 18 Nov 2026.

Performance Over six months the shares gained 22.7%, against +27.6% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue fell 29.3% over the last twelve months (peer median +8.1%); the operating margin is 12.4% (peer median 17.4%).

Valuation It trades at 16.7× forward earnings against a peer median of 20.9× (4th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is -5%, so the hurdle is +21 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.9 points below its cost of capital (8.6% WACC).

Short interest Short interest is 10.2% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 128TFX 126
Six months, rebased to 100: Teleflex against the median of its 20 peers (local-currency closes).

Teleflex financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.26B$1.99B$1.70B$2.97B$2.79B
Revenue growth—+17%-43%+7%—
Gross profit$1.47B$1.13B$1.04B$1.65B$1.56B
EBITDA$401M$455M$414M$816M$778M
Net income$305M-$906M$69.7M$356M$363M
Free cash flow$388M$245M$545M$419M$264M
Capital expenditure$55.1M$95.2M$90.4M$91.4M$79.2M
Total debt$1.68B$2.73B$1.74B$1.95B$1.85B

Quarterly statements and history in the cockpit →

Teleflex competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%0%+20%LNTHCOHCTECYPSN7747688617BLCOGETI-B300832HAE68697701LIVNMMSI300677DIAMMEDSHCGMEDGRALTFX6-month return →1-month return →
Up and to the right = strong over both horizons. Teleflex is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%20×30×40×LNTHCOHCTECYPSN7747688617BLCOGETI-B300832HAE6869LIVNMMSI300677MMEDSHCGMEDTFXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Teleflex is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%LNTHCOHCTEC7747688617BLCOGETI-B300832HAE6869LIVN300677DIAGMEDTFXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Teleflex is the large dot.

Teleflex competitors and peer comparison

Head to head with its named competitors (TFX vs BDX vs MDT vs ICUI)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Teleflex TFX$6.58B+23%-29%12%16.7×16.5%
Becton Dickinson BDX$58.9B+48%-7%16%16.3×-1.6%
Medtronic MDT$129B+30%+10%20%16.8×9.1%
ICU Medical ICUI$4.46B+38%-6%8%19.4×18.9%

How Teleflex compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Teleflex against its 20 peers (data as of 18 Nov 2026)
MeasureTFXPeer medianRank in peer set
1-month return+26.5%+8.5%2nd highest of 21
6-month return+22.7%+27.6%6th lowest of 21
Distance from 52-week high-0.5%-7.2%2nd highest of 21
Revenue growth (TTM)-29.3%+8.1%lowest of 21
Operating margin12.4%17.4%3rd lowest of 21
Forward P/E16.7×20.9×4th cheapest of 20
Growth the price implies (Req g, 7 yrs)16.5%9.0%3rd most demanding of 18
Growth delivered (Del g)-4.7%+9.3%2nd lowest of 18
Hurdle (Req g minus delivered)+21.2 pp+1.8 ppmost demanding of 18
ROIC minus cost of capital-3.9 pp+3.2 pp2nd lowest of 21
EV / EBITDA19.5×13.4×3rd most expensive of 17
Net debt / EBITDA3.1×0.5×3rd most indebted of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Teleflex TFXUnited States$6.58B+23%-29%12%16.7×16.5%-4.7%
Lantheus LNTHUnited States$6.67B+6%+2%19%15.5×0.4%+35.3%
Cochlear COH.AXAustralia$6.72B+58%-1%13%29.1×23.9%+9.3%
ConvaTec CTEC.LUnited Kingdom$6.78B+37%+2%16%17.7×17.2%+4.6%
Ypsomed YPSN.SWSwitzerland$6.83B+27%-13%30%31.7×n/an/a
Asahi Intecc 7747.TJapan$7.09B+24%+23%32%29.7×15.1%+18.8%
APT Medical 688617.SSChina$6.06B+23%+28%37%38.6×9.0%+40.1%
Bausch + Lomb BLCO.TOCanada$7.41B+35%+11%9%18.3×12.0%+10.0%
Getinge GETI-B.STSweden$7.45B+40%-4%14%21.1×5.0%+3.2%
Shenzhen New Industries Biomedical Engineering 300832.SZChina$7.50B+21%+7%43%26.9×2.9%+15.7%
Haemonetics HAEUnited States$5.59B+106%+4%19%20.7×10.9%+8.9%
Sysmex 6869.TJapan$8.06B+58%+8%13%32.0×4.4%+10.4%
Shimadzu 7701.TJapan$8.14B+24%+8%14%21.0×8.3%+7.3%
LivaNova LIVNUnited States$5.21B+28%+12%15%20.9×14.2%+8.2%
Merit Medical Systems MMSIUnited States$5.15B+33%+9%14%19.1×12.6%+9.5%
Intco Medical Technology 300677.SZChina$4.82B-2%+33%20%18.5×-3.5%-6.4%
DiaSorin DIA.MIItaly$4.81B+24%-3%24%20.5×4.1%+6.3%
MiniMed MMEDUnited States$4.78B+46%+14%14%26.3×n/an/a
Sotera Health SHCUnited States$4.65B+5%+7%37%15.7×14.4%+7.3%
Globus Medical GMEDUnited States$9.34B-16%+13%23%13.7×4.6%+30.1%
GRAIL GRALUnited States$4.59B+67%+17%-332%n/an/an/a

Questions

Who are Teleflex's main competitors?
Named competitors: Becton Dickinson (BDX), Medtronic (MDT), ICU Medical (ICUI). The cockpit's measured peer set (industry) also includes Lantheus (LNTH), Cochlear (COH.AX), ConvaTec (CTEC.L), Ypsomed (YPSN.SW), Asahi Intecc (7747.T), APT Medical (688617.SS).
Is Teleflex expensive compared with its peers?
On forward p/e it trades at 16.7× against a peer median of 20.9×, 4th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is -5%, so the hurdle is +21 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Teleflex stock performed?
Over six months to 18 Nov 2026 the shares returned +22.7% against +27.6% for the median peer; over one year +59.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.